SI2303264T1 - Methods for treating alpha-adrenergic mediated states using imidazoline derivatives - Google Patents
Methods for treating alpha-adrenergic mediated states using imidazoline derivatives Download PDFInfo
- Publication number
- SI2303264T1 SI2303264T1 SI200931858T SI200931858T SI2303264T1 SI 2303264 T1 SI2303264 T1 SI 2303264T1 SI 200931858 T SI200931858 T SI 200931858T SI 200931858 T SI200931858 T SI 200931858T SI 2303264 T1 SI2303264 T1 SI 2303264T1
- Authority
- SI
- Slovenia
- Prior art keywords
- imidazol
- dihydro
- amine
- pain
- compound
- Prior art date
Links
- 230000001800 adrenalinergic effect Effects 0.000 title claims 2
- 150000002462 imidazolines Chemical class 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 11
- 208000002193 Pain Diseases 0.000 claims abstract 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- JIDZRCXAOPXSOA-UHFFFAOYSA-N n-[(2,3-dichlorophenyl)methyl]-4,5-dihydro-1h-imidazol-2-amine Chemical compound ClC1=CC=CC(CNC=2NCCN=2)=C1Cl JIDZRCXAOPXSOA-UHFFFAOYSA-N 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- -1 N- (2,3-dimethyl- benzyl) -4,5- dihydro- 1H- imidazol-2- - (2-trifluoromethyl-benzyl) -4,5-dihydro-1H-imidazol-2-amine Chemical compound 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- FAZJLHIWDURSSG-UHFFFAOYSA-N n-[(2,3-dimethoxyphenyl)methyl]-4,5-dihydro-1h-imidazol-2-amine Chemical compound COC1=CC=CC(CNC=2NCCN=2)=C1OC FAZJLHIWDURSSG-UHFFFAOYSA-N 0.000 claims 1
- ZBYXEIJRCMVSAM-UHFFFAOYSA-N n-[(2,3-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazol-2-amine Chemical compound CC1=CC=CC(CNC=2NCCN=2)=C1C ZBYXEIJRCMVSAM-UHFFFAOYSA-N 0.000 claims 1
- PJIDEBRTKIMRCU-UHFFFAOYSA-N n-[(2-chloro-3-fluorophenyl)methyl]-4,5-dihydro-1h-imidazol-2-amine Chemical compound FC1=CC=CC(CNC=2NCCN=2)=C1Cl PJIDEBRTKIMRCU-UHFFFAOYSA-N 0.000 claims 1
- RRUAZGCMEWATRC-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-4,5-dihydro-1h-imidazol-2-amine Chemical compound ClC1=CC=CC=C1CNC1=NCCN1 RRUAZGCMEWATRC-UHFFFAOYSA-N 0.000 claims 1
- WHBYJUBYIGQXEV-UHFFFAOYSA-N n-[(2-fluorophenyl)methyl]-4,5-dihydro-1h-imidazol-2-amine Chemical compound FC1=CC=CC=C1CNC1=NCCN1 WHBYJUBYIGQXEV-UHFFFAOYSA-N 0.000 claims 1
- IFRIBOQFELMEFF-UHFFFAOYSA-N n-[(2-methylphenyl)methyl]-4,5-dihydro-1h-imidazol-2-amine Chemical compound CC1=CC=CC=C1CNC1=NCCN1 IFRIBOQFELMEFF-UHFFFAOYSA-N 0.000 claims 1
- FBJSRMPJBSZRJU-UHFFFAOYSA-N n-[(3-bromo-2-methoxyphenyl)methyl]-4,5-dihydro-1h-imidazol-2-amine Chemical compound COC1=C(Br)C=CC=C1CNC1=NCCN1 FBJSRMPJBSZRJU-UHFFFAOYSA-N 0.000 claims 1
- UTPFXZUVUHYVFE-UHFFFAOYSA-N n-[[2-(difluoromethoxy)phenyl]methyl]-4,5-dihydro-1h-imidazol-2-amine Chemical compound FC(F)OC1=CC=CC=C1CNC1=NCCN1 UTPFXZUVUHYVFE-UHFFFAOYSA-N 0.000 claims 1
- JZHBZAULPDFTLR-UHFFFAOYSA-N n-[[2-(trifluoromethoxy)phenyl]methyl]-4,5-dihydro-1h-imidazol-2-amine Chemical compound FC(F)(F)OC1=CC=CC=C1CNC1=NCCN1 JZHBZAULPDFTLR-UHFFFAOYSA-N 0.000 claims 1
- IQGVHIHXSHPHKU-UHFFFAOYSA-N n-[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]-4,5-dihydro-1h-imidazol-2-amine Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1CNC1=NCCN1 IQGVHIHXSHPHKU-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5983708P | 2008-06-09 | 2008-06-09 | |
| PCT/US2009/046432 WO2009152052A1 (en) | 2008-06-09 | 2009-06-05 | Methods of treating alpha adrenergic mediated conditions |
| EP09763343.2A EP2303264B1 (en) | 2008-06-09 | 2009-06-05 | Methods of treating alpha adrenergic mediated conditions using imidazoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2303264T1 true SI2303264T1 (en) | 2018-08-31 |
Family
ID=40823137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200931858T SI2303264T1 (en) | 2008-06-09 | 2009-06-05 | Methods for treating alpha-adrenergic mediated states using imidazoline derivatives |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8071636B2 (https=) |
| EP (3) | EP2303264B1 (https=) |
| JP (1) | JP5571072B2 (https=) |
| CN (1) | CN102099032B (https=) |
| AU (1) | AU2009257692A1 (https=) |
| CA (3) | CA2959793A1 (https=) |
| DK (2) | DK2932968T3 (https=) |
| ES (2) | ES2672777T3 (https=) |
| HU (1) | HUE039357T2 (https=) |
| PL (2) | PL2303264T3 (https=) |
| PT (2) | PT2303264T (https=) |
| SI (1) | SI2303264T1 (https=) |
| TR (1) | TR201802766T4 (https=) |
| WO (1) | WO2009152052A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120083508A1 (en) * | 2006-12-22 | 2012-04-05 | Allergan, Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
| US7902247B2 (en) * | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| PL2605771T3 (pl) * | 2010-08-16 | 2018-10-31 | Allergan, Inc. | Sposób aktywacji limfocytów t regulacyjnych za pomocą agonistów receptorów alfa-2b-adrenergicznych |
| JP6756435B2 (ja) * | 2014-03-31 | 2020-09-16 | ザ スクリプス リサーチ インスティテュート | Ｔｒａｉｌ誘導のためのファーマコフォア |
| EP3700536A4 (en) | 2017-10-27 | 2021-11-17 | Shanghai Yao Yuan Biotechnology Co., Ltd. | COMPOSITIONS AND PROCEDURES FOR MODULATING IMMUNE REACTION BY ACTIVATING ALPHA-PROTEIN KINASE 1 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6708160A (https=) * | 1966-06-30 | 1968-01-02 | ||
| DE2259160A1 (de) * | 1972-12-02 | 1974-06-06 | Boehringer Sohn Ingelheim | Neue substituierte 2-phenylaminoimidazoline, deren saeureadditionssalze und verfahren zur herstellung derselben sowie ihre verwendung als arzneimittel |
| US4256755A (en) | 1980-04-28 | 1981-03-17 | E. I. Du Pont De Nemours & Company | Method of using N-substituted dihydro-2-oxazolamines as analgesics |
| FR2806082B1 (fr) * | 2000-03-07 | 2002-05-17 | Adir | Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2002089794A1 (en) * | 2001-05-07 | 2002-11-14 | Universite Catholique De Louvain | Method for treating neuropathic pain and pharmaceutical preparation therefor |
| EP1333028A1 (en) * | 2002-01-31 | 2003-08-06 | Boehringer Ingelheim Pharma GmbH & Co.KG | 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence |
| US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
| CN101287366A (zh) | 2005-05-19 | 2008-10-15 | 拜尔农作物科学股份公司 | 杀虫的取代的苄基氨基杂环及杂芳基衍生物 |
| WO2008123821A1 (en) * | 2007-03-01 | 2008-10-16 | Albireo Ab | 4, 5-dihydro-lh-imidazol-2-amine derivatives for use in the treatment of respiratory, cardiovascular, neurological or gastrointestinal disorders |
| CN101687812A (zh) * | 2007-07-02 | 2010-03-31 | 弗·哈夫曼-拉罗切有限公司 | 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物 |
| WO2009052075A2 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating motor disorders with alpha-2b adrenergic receptor agonists |
-
2009
- 2009-06-05 ES ES09763343.2T patent/ES2672777T3/es active Active
- 2009-06-05 WO PCT/US2009/046432 patent/WO2009152052A1/en not_active Ceased
- 2009-06-05 CN CN200980126849.0A patent/CN102099032B/zh not_active Expired - Fee Related
- 2009-06-05 AU AU2009257692A patent/AU2009257692A1/en not_active Abandoned
- 2009-06-05 SI SI200931858T patent/SI2303264T1/en unknown
- 2009-06-05 PL PL09763343T patent/PL2303264T3/pl unknown
- 2009-06-05 CA CA2959793A patent/CA2959793A1/en not_active Abandoned
- 2009-06-05 US US12/479,129 patent/US8071636B2/en active Active
- 2009-06-05 PL PL15165926T patent/PL2932968T3/pl unknown
- 2009-06-05 JP JP2011513592A patent/JP5571072B2/ja not_active Expired - Fee Related
- 2009-06-05 ES ES15165926.5T patent/ES2665293T3/es active Active
- 2009-06-05 TR TR2018/02766T patent/TR201802766T4/tr unknown
- 2009-06-05 EP EP09763343.2A patent/EP2303264B1/en active Active
- 2009-06-05 EP EP15165926.5A patent/EP2932968B1/en active Active
- 2009-06-05 DK DK15165926.5T patent/DK2932968T3/en active
- 2009-06-05 EP EP11174152A patent/EP2377534A1/en not_active Withdrawn
- 2009-06-05 HU HUE09763343A patent/HUE039357T2/hu unknown
- 2009-06-05 PT PT97633432T patent/PT2303264T/pt unknown
- 2009-06-05 PT PT151659265T patent/PT2932968T/pt unknown
- 2009-06-05 CA CA2744929A patent/CA2744929C/en active Active
- 2009-06-05 CA CA3133261A patent/CA3133261A1/en not_active Abandoned
- 2009-06-05 DK DK09763343.2T patent/DK2303264T3/en active
-
2011
- 2011-10-17 US US13/274,471 patent/US20120035235A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT2932968T (pt) | 2018-03-13 |
| EP2932968B1 (en) | 2018-01-17 |
| AU2009257692A1 (en) | 2009-12-17 |
| DK2303264T3 (en) | 2018-05-22 |
| EP2303264A1 (en) | 2011-04-06 |
| US8071636B2 (en) | 2011-12-06 |
| JP5571072B2 (ja) | 2014-08-13 |
| WO2009152052A8 (en) | 2010-11-11 |
| WO2009152052A1 (en) | 2009-12-17 |
| CA2744929C (en) | 2017-07-25 |
| JP2011522893A (ja) | 2011-08-04 |
| TR201802766T4 (tr) | 2018-03-21 |
| PL2303264T3 (pl) | 2018-08-31 |
| ES2665293T3 (es) | 2018-04-25 |
| EP2932968A1 (en) | 2015-10-21 |
| ES2672777T3 (es) | 2018-06-18 |
| HK1214132A1 (en) | 2016-07-22 |
| PL2932968T3 (pl) | 2018-06-29 |
| US20090306161A1 (en) | 2009-12-10 |
| CA2959793A1 (en) | 2009-12-17 |
| CA3133261A1 (en) | 2009-12-17 |
| CN102099032B (zh) | 2014-07-09 |
| EP2303264B1 (en) | 2018-04-04 |
| CN102099032A (zh) | 2011-06-15 |
| EP2377534A1 (en) | 2011-10-19 |
| DK2932968T3 (en) | 2018-03-12 |
| PT2303264T (pt) | 2018-05-14 |
| HUE039357T2 (hu) | 2018-12-28 |
| CA2744929A1 (en) | 2009-12-17 |
| US20120035235A1 (en) | 2012-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2485131C2 (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства | |
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
| SI2303264T1 (en) | Methods for treating alpha-adrenergic mediated states using imidazoline derivatives | |
| SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
| HRP20120129T1 (hr) | Hidroksimetil pirolidini kao agonisti beta 3 adrenergičkog receptora | |
| CA2674436A1 (en) | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors | |
| CA2565813A1 (en) | Substituted methyl aryl or heteroaryl amide compounds | |
| MA32727B1 (fr) | Pyrazolylaminopyridines au titre d'inhibiteurs de fak | |
| RU2400483C2 (ru) | Пуриновые производные в качестве агонистов рецептора a2a | |
| JP2016528301A5 (https=) | ||
| HRP20200836T1 (hr) | Liječenje bolesti povezanih s imunitetom i upalnih bolesti | |
| KR20010079616A (ko) | 과도한 물질 ｐ에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도 | |
| NZ601077A (en) | Use of an adrenal hormone-modifying agent | |
| CA2409741A1 (en) | Tnf-.alpha. production inhibitors | |
| JP2002522359A5 (https=) | ||
| MA38315A1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
| JP2014507443A5 (https=) | ||
| CA2777746A1 (en) | Benzoimidazole compounds and uses thereof | |
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| EA022994B1 (ru) | Способ подавления толерантности к опиоидному анальгетику | |
| RU2011112684A (ru) | АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α | |
| CA2643005A1 (en) | Imidazole-5-carboxylic acid derivatives,the preparation method therefor and the uses thereof | |
| MA33166B1 (fr) | Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose | |
| RU2015127624A (ru) | Производное гидантоина |